VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Exelixis reports preliminary data from cabozantinib phase 1b trial on RCC

Exelixis, Inc. today reported preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma (RCC) participating in an ongoing phase 1b trial of cabozantinib.

3 Feb 2012

Circadian's VGX-100 human antibody improves corneal graft survival

Circadian Technologies Limited announced today the publication of data in the scientific journal, Investigative Ophthalmology & Visual Science (IOVS), showing that VEGF-C expression is markedly up-regulated in corneal graft rejection.

30 Jan 2012

Positive preliminary data from Exelixis' cabozantinib phase 2 trial on HCC

Exelixis, Inc. today reported positive preliminary data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.

20 Jan 2012

Study shows 50% reduction in blindness and severe visual loss in Denmark

Age-related macular degeneration (AMD) is the most frequent cause of blindness in the Western World. A report from the University of Copenhagen and Glostrup Hospital in Denmark published today shows the number of new cases of blindness and severe visual loss in Denmark has been halved during the last ten years.

20 Jan 2012

ForSight VISION4 to receive first milestone payment for Lucentis drug delivery device

Genentech, a member of the Roche Group, today announced it will make its first milestone payment to ForSight VISION4, Inc. as part of an exclusive license agreement to develop the company's investigational drug delivery device, designed to provide sustained delivery of Lucentis (ranibizumab).

13 Jan 2012

New possibilities for effective treatment of psoriasis

Researchers at Link-ping University in Sweden are now launching a plan to effectively treat psoriasis.

11 Jan 2012

SANUWAVE PACE technology reverses negative effects of ischemic, reperfusion injuries

SANUWAVE Health, Inc., today reported publication of peer-reviewed, preclinical data conducted at Cleveland Clinic that demonstrate the ability of the Company's Pulsed Acoustic Cellular Expression (PACE®) technology to substantially decrease the detrimental effects of microcirculatory injury for certain ischemic (lack of blood flow) and reperfusion (restoration of blood flow) injuries.

11 Jan 2012

Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

SFJ Pharma Ltd. II announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial in Asia of Pfizer's investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.

9 Jan 2012

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

KalVista Pharmaceuticals and JDRF have formed a research partnership focused on a novel approach being developed by KalVista to preserve vision and slow the progression of diabetic eye disease.

9 Jan 2012

Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

Circadian Technologies Limited announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre.

9 Jan 2012

Regeneron, Genentech enter non-exclusive license and partial settlement agreement for EYLEA

Regeneron Pharmaceuticals, Inc. today announced that the Company has entered into a non-exclusive license and partial settlement agreement with Genentech, Inc., a member of the Roche Group relating to U.S. ophthalmic sales of EYLEA (aflibercept) Injection.

3 Jan 2012

Astellas, AVEO announce results of tivozanib and sorafenib comparison trial on RCC

AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that tivozanib demonstrated superiority over sorafenib in the primary endpoint of progression-free survival (PFS) in TIVO-1, a global, randomized Phase 3 clinical trial evaluating the efficacy and safety of investigational drug tivozanib compared to sorafenib in 517 patients with advanced renal cell carcinoma.

3 Jan 2012

Van Andel studies distinguish cancer subtypes and provide promising new drug targets

Two recent studies by Van Andel Research Institute scientists are providing a foundation for a more complete understanding of distinct kidney cancer subtypes, which could pave the way for better treatments.

30 Dec 2011

GOG targeted therapy phase 3 clinical trial delays progression of advanced ovarian cancer

Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer.

29 Dec 2011

AVEO initiates enrollment in tivozanib and mFOLFOX6 Phase 2 combination trial for CRC

AVEO Pharmaceuticals, Inc. today announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called BATON-CRC, evaluating tivozanib in combination with modified FOLFOX6 (mFOLFOX6) compared to bevacizumab in combination with mFOLFOX6 as first-line therapy in patients with advanced metastatic colorectal cancer.

22 Dec 2011

EETs may also drive growth and spread of cancer

A group of small molecules called EETs - currently under scrutiny as possible treatment targets for a host of cardiovascular diseases - may also drive the growth and spread of cancer, according to researchers at the Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and other institutions.

20 Dec 2011

Blocking EETs may represent novel strategy for cancer therapy

Recent findings in mice suggest that blocking the production of small molecules produced in the body, known as epoxyeicosatrienoic acids (EETs), may represent a novel strategy for treating cancer by eliminating the blood vessels that feed cancer tumors.

20 Dec 2011

Combination of bevacizumab and chemoradiation safe, effective for nasopharyngeal carcinoma

The trial conducted by the Radiation Therapy Oncology Group (RTOG) shows the feasibility to deliver bevacizumab to the current chemoradiation standard without any apparent increased adverse side effects.

17 Dec 2011

First reliable method to predict whether SSRIs work on depressed patients

Loyola University Medical Center researchers are reporting what could become the first reliable method to predict whether an antidepressant will work on a depressed patient.

16 Dec 2011

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that they have initiated a Phase 3 clinical trial evaluating the efficacy and safety of EYLEA (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

28 Nov 2011

VEGF News and Research

Further Reading

Exelixis reports preliminary data from cabozantinib phase 1b trial on RCC

Circadian's VGX-100 human antibody improves corneal graft survival

Positive preliminary data from Exelixis' cabozantinib phase 2 trial on HCC

Study shows 50% reduction in blindness and severe visual loss in Denmark

ForSight VISION4 to receive first milestone payment for Lucentis drug delivery device

New possibilities for effective treatment of psoriasis

SANUWAVE PACE technology reverses negative effects of ischemic, reperfusion injuries

Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

Regeneron, Genentech enter non-exclusive license and partial settlement agreement for EYLEA

Astellas, AVEO announce results of tivozanib and sorafenib comparison trial on RCC

Van Andel studies distinguish cancer subtypes and provide promising new drug targets

GOG targeted therapy phase 3 clinical trial delays progression of advanced ovarian cancer

AVEO initiates enrollment in tivozanib and mFOLFOX6 Phase 2 combination trial for CRC

EETs may also drive growth and spread of cancer

Blocking EETs may represent novel strategy for cancer therapy

Combination of bevacizumab and chemoradiation safe, effective for nasopharyngeal carcinoma

First reliable method to predict whether SSRIs work on depressed patients

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Latest eBooks

Industry focus eBook - The Digital Laboratory (4th edition)

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (3rd Edition)

BFEB: Advances in microplate-based assays and analysis

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation